EMBC EBITDA | EMBECTA CORP.

Embecta Corp. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

Embecta Corp. ebitda for the quarter ending 2026-06-30 was $59.3M, a 42.54% decline year-over-year.
Embecta Corp. ebitda for the quarter ending 2026-03-31 was $45.2M, a 37.13% decline year-over-year.
Embecta Corp. ebitda for the quarter ending 2025-12-31 was $93.6M, a 145.67% increase year-over-year.
Embecta Corp. ebitda for the quarter ending 2025-09-30 was $69.6M, a 94.96% increase year-over-year.
Embecta Corp. ebitda for fiscal 2025 was $282.8M, a 39.31% increase from fiscal 2024.
Embecta Corp. ebitda for fiscal 2024 was $203M, a 20.11% decline from fiscal 2023.
Embecta Corp. ebitda for fiscal 2023 was $254.1M, a 25.55% decline from fiscal 2022.
Embecta Corp. ebitda for fiscal 2022 was $341.3M, a 35.64% decline from fiscal 2021.

Available history: 2020-09-30 to 2026-06-30
Data captured: 2026-06-30

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$59.3M	$48.7M	$10.6M	(m)	(m)	$1.10M*	$41.80M*	$118.40M	$5.60M	$78.60M	$6.50M
2026-03-31	Reported	$45.2M	$35M	$10.2M	(m)	(m)	$500.00K*	$31.10M*	$94.00M	$5.40M	$76.20M	$13.60M
2025-12-31	Reported	$93.6M	$83.3M	$10.3M	(m)	35.83%	$600.00K	$17.20M	$99.50M	$4.60M	$77.60M	$14.80M
2025-09-30	Reported	$69.6M	$56.5M	$13.1M	(m)	26.36%	(m)	(m)	(m)	(m)	(m)	(m)
2025-06-30	Reported	$103.2M	$94M	$9.2M	(m)	(m)	$400.00K*	$81.20M*	$98.40M	$4.40M	$84.40M	$26.70M
2025-03-31	Reported	$71.9M	$62.9M	$9M	(m)	(m)	$100.00K*	$31.80M*	$94.90M	$8.00M	$79.60M	$12.30M
2024-12-31	Reported	$38.1M	$28.7M	$9.4M	(m)	14.55%	$1.50M	-$5.30M	$104.80M	$20.30M	$81.10M	-$700.00K
2024-09-30	Reported	$35.7M	$26.2M	$9.5M	(m)	12.48%	(m)	(m)	(m)	(m)	(m)	(m)
2024-06-30	Reported	$64.8M	$55.9M	$8.9M	(m)	(m)	$9.70M*	-$2.10M*	$82.40M	$20.40M	$85.70M	$12.30M
2024-03-31	Reported	$48.2M	$39.2M	$9M	(m)	(m)	$3.40M*	$24.30M*	$101.80M	$18.40M	$92.30M	-$19.00M
2023-12-31	Reported	$54.3M	$45.5M	$8.8M	(m)	19.58%	$2.70M	-$13.10M	$91.40M	$20.20M	$90.30M	-$5.80M
2023-09-30	Reported	$35.1M	$25.8M	$9.3M	(m)	12.45%	(m)	(m)	(m)	(m)	(m)	(m)
2023-06-30	Reported	$59.4M	$51.3M	$8.1M	(m)	(m)	$6.80M*	-$9.30M*	$96.60M	$22.60M	$87.60M	$4.90M
2023-03-31	Reported	$63.6M	$55.6M	$8M	(m)	(m)	$5.80M*	-$13.00M*	$87.30M	$22.10M	$85.20M	$10.50M
2022-12-31	Reported	$96M	$88.8M	$7.2M	(m)	34.82%	$4.70M	$60.40M	$86.90M	$16.90M	$72.80M	$20.90M
2022-09-30	Reported	$4.5M	-$3M	$7.5M	(m)	1.64%	(m)	(m)	(m)	(m)	(m)	(m)
2022-06-30	Reported	$106.2M	$97.1M	$9.1M	(m)	(m)	$5.30M*	$32.80M*	$88.20M	$14.30M	$83.80M	$11.20M
2022-03-31	Reported	$105.6M	$98.9M	$6.7M	(m)	(m)	$5.40M*	$182.60M*	$83.30M	$18.00M	$66.90M	$14.30M
2021-12-31	Reported	$125M	$116.6M	$8.4M	(m)	43.21%	$4.30M	$138.80M	$85.40M	$16.70M	$62.20M	$17.80M
2021-09-30	Reported	$126.1M	$117.2M	$8.9M	(m)	41.92%	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Reported	$134.2M	$124.3M	$9.9M	(m)	(m)	$7.40M*	$129.70M*	$92.40M	$15.70M	$60.50M	$20.20M
2021-03-31	Reported	$136.6M	$126.4M	$10.2M	(m)	(m)	$5.20M*	$119.70M*	$87.90M	$14.10M	$55.80M	$20.60M
2020-12-31	Reported	$133.4M	$124.1M	$9.3M	(m)	46.76%	$11.40M	$121.40M	$94.00M	$14.00M	$53.20M	$19.80M

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-09-30	Reported	$282.8M	$242.1M	$40.7M	(m)	26.18%	$9.30M	$191.70M	$403.60M	$37.30M	$332.00M	$40.90M
2024-09-30	Reported	$203M	$166.8M	$36.2M	(m)	18.07%	$15.80M	$35.70M	$387.90M	$78.80M	$365.10M	-$34.10M
2023-09-30	Reported	$254.1M	$221.5M	$32.6M	(m)	22.67%	$26.50M	$67.70M	$370.90M	$85.20M	$341.30M	$35.30M
2022-09-30	Reported	$341.3M	$309.6M	$31.7M	(m)	30.22%	$23.60M	$412.20M	$354.60M	$66.90M	$294.80M	$33.00M
2021-09-30	Reported	$530.3M	$492M	$38.3M	(m)	45.51%	$36.80M	$456.30M	$364.90M	$63.30M	$240.30M	$80.10M
2020-09-30	Reported	$524.8M	$486.5M	$38.3M	(m)	48.35%	$41.90M	$498.50M	$322.90M	$61.40M	$214.70M	$58.20M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
TREACE MEDICAL CONCEPTS, INC. (TMCI)	United States	$0.297B	-4.32
Mobia Medical, Inc. (MOBI)	United States	$0.293B
TriSalus Life Sciences, Inc. (TLSI)	United States	$0.283B	-9.92
SHOULDER INNOVATIONS, INC. (SI)	United States	$0.355B
Orchestra BioMed Holdings, Inc. (OBIO)	United States	$0.356B	-4.39
Cytosorbents Corp (CTSO)	United States	$0.274B	-1.29
ORASURE TECHNOLOGIES INC (OSUR)	United States	$0.272B	-6.26
Anika Therapeutics, Inc. (ANIK)	United States	$0.272B	-51.71
Orthofix Medical Inc. (OFIX)		$0.373B
InfuSystem Holdings, Inc (INFU)	United States	$0.253B	22.52